EarlyDx is committed to providing cutting-edge non-invasive genomics technologies and best-in-class early disease diagnostics. Our proprietary cfDNA-based technologies, in combination with powerful AI algorithms, have shown great potential to transform non-invasive biomarker discovery, diagnostics, and precision medicine for almost any diseases, including cancers, aging, metabolic diseases, autoimmune diseases, imprinting diseases, and neurological diseases. Our key cfDNA-based best-in-class technologies include: 1. cfMethyl-seq: a powerful and cost-effective NGS solution to profile the cfDNA methylome 2. cfSNV: a cutting-edge computational tool to accurately call mutations directly from blood 3. cfTrack: for non-invasive monitoring of cancer MRD, recurrence, and evolution 4. EarlyDx-Cloud: a comprehensive bioinformatics data analysis platform for liquid biopsy Please check out our relevant publications in details: https://earlydx.com/technologies/publications/